MedTrace Logo

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

NCT02452307 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-08-17

No results posted yet for this study

Summary

The study evaluates the prostate-specific antigen (PSA) response in HLA-A\*02 positive patients with biochemical recurrence after radical prostatectomy treated with a prostate-specific peptide vaccine in combination with different immune-adjuvants.

Conditions

  • Recurrent Prostate Cancer

Interventions

BIOLOGICAL

Peptide vaccine

subcutaneous

DRUG

Montanide ISA-51

subcutaneous

DRUG

Granulocyte macrophage colony stimulating factor (GM-CSF)

intradermal

DRUG

Imiquimod

epicutaneous

DRUG

mRNA

subcutaneous

DRUG

Protamin

subcutaneous

PROCEDURE

local hyperthermia

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Arnulf Stenzl, Prof. · Department of Urology, University of Tuebingen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2017-10-31
Completion
2017-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02452307 on ClinicalTrials.gov